We’re excited to present new SER-155 Phase 1b exploratory biomarker data at #ASCO25. If you’re attending, we welcome you to stop by our poster and learn more!. Read more:

This morning we shared our Q1 results and business updates. SER-155 is planning for a Phase 2 following FDA feedback, with new exploratory biomarker data supporting its potential in BSIs and broader immune/inflammatory diseases. Strategic partnership discussions for SER-155 are

We’re looking forward to sharing our Q1 2025 financial results and business updates this Wednesday, May 7 at 8:30am EST. Dial-in info can be found in our recent release:

Digestive Disease Week is just around the corner! Our team will be presenting three posters highlighting new results that could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases,

Seres will be at #EBMT25 sharing data from our Phase 1b placebo-controlled study of SER-155 in allo-HSCT patients. Poster abstract (A178): Oral presentation abstract (OS16-01):

This morning we reported Q4 and full year 2024 earnings. In addition, we shared updates regarding upcoming milestones for our lead live biotherapeutic, SER-155. Read more in the full release: View the webcast replay:

Tomorrow morning our team will host a conference call and live video webcast to review our Q4 and full-year 2024 financial results, along with key business updates. Check out our press release for dial-in info:

RT @FlagshipPioneer: “We’ve got the right technology, the right team, the right science to change lives, and we're in the process of doing….

We're excited to be back in San Francisco for #JPM2025!. Join Seres Therapeutics on Thursday, January 16th at 7:30 AM PST for a company overview highlighting our plans to advance our pipeline, including SER-155.

Today we're thrilled to announce that our lead live biotherapeutic, SER-155, has received Breakthrough Therapy Designation from the FDA for the reduction of blood stream infections in adults undergoing an allogeneic stem cell transplant. Read more:

Our CEO Eric Shaff will be participating in a fireside chat at the upcoming Piper Sandler Annual Healthcare Conference on December 3rd. Read the release:

Today we reported our Q3 financial results and provided business updates, including planned next steps for SER-155 following encouraging Phase 1b data in allo-HSCT patients. Read more in the full release:

Today we’re pleased to share Cohort 2 data from our Phase 1b study evaluating SER-155 in patients undergoing allo-HSCT. Read the full release:

Today we're excited to announce that we've signed the VOWST asset purchase agreement with Nestlé. The completion of the transaction, which is subject to Seres’ shareholder approval and other customary conditions, is expected to occur in the next 90 days. Read the full release:

Our team had a great time at Friday’s #BioBall event, sponsored by Special Olympics Massachusetts. Not only was it fun to get together, but we helped raise money to support our local #SpecialOlympics athletes!. Learn more about the cause:  

Today, we entered into an agreement w/ partner @NestleHealthUS to acquire Vowst, a deal that allows us to focus on our pioneering mission of advancing revolutionary microbiome therapeutics for as many patients as possible.

Seres is excited to present new preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at #ASCO24 in Chicago. Join us at the poster session on June 3rd at 9am

Seres has completed enrollment for Cohort 2 of the Phase 1b clinical trial of SER-155 in Allo #HSCT patients, bringing us closer to potentially revolutionizing the approach to enteric-derived and bloodstream infections post-transplantation.

We are excited to present at #TANDEM24 in San Antonio. Join us at the poster session on Feb 22nd at 6:45pm CST to learn about preliminary data from our currently enrolling Phase 1b study of investigational #microbiome therapeutic SER-155. Learn more:

At Seres, we have been pioneering the development of microbiome therapeutics since 2011. As a #FlagshipFounded company, we took bold leaps in 2023 to transform the lives of patients as we received FDA approval for the first orally administered microbiome-based therapeutic. We're.